Form 4: AEON Biopharma Director Shelley B. Thunen Acquires Shares and Stock Options

Director Shelley B. Thunen reports acquisition of AEON Biopharma shares and stock options.

Summary

• On August 31, 2024, Shelley B. Thunen, a director of AEON Biopharma, acquired 36,021 shares of Class A Common Stock at $0.
• Thunen also acquired 96,210 stock options with an exercise price of $0.83 on the same date.
• The stock options vest in equal monthly installments over 18 months following the grant date, August 31, 2024, and expire on August 30, 2034.
• The restricted stock units vest in full on the second anniversary of the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option awards to a director. The vesting schedule suggests a long-term commitment.

Positives

• The acquisition of shares and stock options by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a long-term commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, AEON Biopharma, Director, Shelley B. Thunen, Acquisition